ELVN - Company ID 0001672619
Enliven Therapeutics, Inc. trades as ELVN and has a market capitalization of $3.06 B, making it the #1809 largest US-listed company by market value. This page tracks Enliven Therapeutics, Inc. through 749 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
Enliven Therapeutics to Present at Upcoming Investor Conferences | Enliven Therapeutics
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | Enliven Therapeutics
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Enliven Therapeutics
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Enliven Therapeutics
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Enliven Therapeutics
The largest companies sharing Enliven Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Enliven Therapeutics, Inc. (ELVN) has a market capitalization of $3.06 B as of 2026-07-09, ranking #1809 among US-listed companies.
In its latest fiscal year Enliven Therapeutics, Inc. reported a net loss of $103.70M.